Clinical Trials Logo
NCT number NCT03177460
Study type Interventional
Source M.D. Anderson Cancer Center
Contact Sumit K. Subudhi, MD, PHD
Phone 713-563-1602
Email CR_Study_Registration@mdanderson.org
Status Recruiting
Phase Phase 1
Start date June 7, 2017
Completion date June 2019

Clinical Trial Summary

The goal of this clinical research study is to learn about the safety and tolerability of giving Darzalex (daratumumab) to patients who have prostate cancer before having an already-scheduled prostatectomy (surgical removal of the prostate).

Researchers also want to learn if daratumumab can help to control the disease before the prostatectomy.

This is an investigational study. Daratumumab is FDA approved and commercially available to treat multiple myeloma. It is considered investigational to use daratumumab in patients with prostate cancer.

The study doctor can explain how the study drug is designed to work.

Up to 15 participants will be enrolled in this study. All will take part at MD Anderson.


Clinical Trial Description

Study Drug Administration:

If you are found to be eligible to take part in this study, you will receive daratumumab by vein 1 time each week for 4 weeks before your prostatectomy. During Week 1, your dose of daratumumab will be given over 8 hours. After that, each dose will be given over about 4 hours.

In this study, the following will be done to lower the chance of a daratumumab infusion related reaction:

- You will get medications, including steroids, acetaminophen, and/or antihistamine before the infusion. If you are considered high risk, you may also get medications, including inhaled steroids, after the infusion.

- The infusion may be slowed down or stopped if you have a reaction.

- You may stay overnight in the hospital after the infusion so the study staff can check your health.

You may ask the study staff for more information about the types of medications you will receive to lower your chance of an infusion-related reaction, including how they are administered and their risks.

Length of Study:

You may receive up to 4 doses of daratumumab. You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.

Your participation on the study will be over after the Week 18 visit (described below).

Study Visits:

During Weeks 1-4:

- You will have a physical exam

- Blood (about 2 tablespoons) will be drawn for routine and blood type testing. ┬░Daratumumab treatment will interfere with blood type testing which is needed before blood transfusions can be given. For this reason, a test to find out your blood type will be performed before you receive daratumumab. You should carry the blood type card with you while you are on this study.

- During Week 3 only, blood (about 1-2 teaspoons) will be drawn to check your PSA levels.

During Week 6 (the week of your surgery):

- You will have a physical exam

- Blood (about 2 tablespoons) will be drawn for routine tests, including measurements of your PSA and testosterone levels. Part of this sample will also be used for blood type testing.

- You will have surgery to remove your prostate. You will sign a separate consent form explaining the procedure and its risks in more detail.

End-of-Study Visit:

During Week 18, blood (about 2 tablespoons) will be drawn for routine tests, including measurements of your PSA and testosterone levels.

If you withdrew from the study before Week 18, the study staff may call you to ask how you are doing. This call should last about 5-10 minutes.


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT03177759 - Living With Prostate Cancer (LPC) N/A
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Recruiting NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data N/A
Recruiting NCT02945813 - SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy Phase 2
Recruiting NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A
Completed NCT02124668 - A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Phase 2
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A
Active, not recruiting NCT00779168 - White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy Phase 1
Recruiting NCT02799706 - Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer Phase 3
Recruiting NCT01990196 - Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer Phase 2
Recruiting NCT02766543 - Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer Phase 2
Recruiting NCT03134027 - Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers N/A
Not yet recruiting NCT03263780 - High Resolution PET-MRI Before Prostate Cancer HIFU Early Phase 1
Not yet recruiting NCT03256630 - Evaluation of Urine and Blood Biomarkers to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer N/A
Not yet recruiting NCT03284684 - Kinetics of Perioperative Circulating DNA in Cancer Surgery N/A
Recruiting NCT02906241 - PACCT: Partnering Around Cancer Clinical Trials N/A
Recruiting NCT02886598 - Safety and Efficacy of Firmagon® (Degarelix) for Injection N/A
Recruiting NCT02766686 - Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons N/A
Recruiting NCT02543255 - Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) Phase 2